A new study led by Profs. Fan Kelong and Yan Xiyun from the Institute of Biophysics of the Chinese Academy of Sciences ...

Generation Bio Co. is developing siRNA therapeutics for T cell-driven autoimmune diseases using its T cell-selective lipid nanoparticle technology. This innovative delivery system aims to ...

Recently, the mechanism of cellular uptake, intracellular transport and the endosomal escape of siRNA by SNALP delivery had been investigated. It has been shown that SNALPs entered cells by both ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases- Lead target ...

Multidrug-resistant bacteria pose a major threat to human health. Manipulation of bacterial genes at the transcriptional level is a potential strategy to fight antibiotic-resistant bacterial ...

A key feature of Repair Drive is the use of a small interfering RNA (siRNA) to eliminate the unhealthy cells. Researchers used siRNA to temporarily inhibit an essential gene that is required for ...

In a recent publication in Cell Reports Medicine, a collaborative research team led by Chen-Yu Zhang and Huan Wang at Nanjing ...

RESET uses large-scale human data and AI to identify genes – or transcription factors – that can regulate cell damage. Then, it develops siRNA therapeutics against these targets to return ...

Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research Session Marlborough, ...

40)–siRNA Cell cycle proteins PLK1 (yes) Intrahepatic mouse tumor models and s.c. tumor models [78–80] DSPC:Chol:PEG–C–DMA:cationic lipid (10:40:10:40)–siRNA Factor VII (yes) C57BL/6 mic ...